Arrhythmias & electrophysiology
The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial
Study context
- Population
- Individuals aged ≥65 years with at least one additional risk factor for stroke, randomly identified from the National Population Register of Norwayplanned enrolment
- Participants
- 35,000 individuals
- Planned comparison
- Self-screening for atrial fibrillation (AF) with continuous electrocardiogram (ECG) vs control
- Primary endpoint
- Time to a first stroke (ischaemic or haemorrhagic stroke)
- Follow-up
- 5-year follow-up
Methodological detailsrationale and design, open, siteless, nationwide, First participant enrolled on 1 September 2023, Follow-up through national health registries
- Rationale and design
- Open
- Siteless
- Nationwide
- First participant enrolled on 1 September 2023
- Follow-up through national health registries
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial. Europace. Published 9 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →